Related Experiment Videos
Conjugated estrogens and hypercoagulability.
American Journal of Obstetrics and Gynecology
|July 15, 1975
Summary
Conjugated estrogens in menopausal women showed a slight shift toward hypercoagulability, indicated by thrombelastograms. Antithrombin III activity decreased less than with oral contraceptives, with some fibrin monomers appearing early in therapy.
Area of Science:
- Endocrinology
- Hematology
- Thrombosis Research
Background:
- Menopausal hormone therapy, including conjugated estrogens, is widely used.
- Estrogen therapy's impact on coagulation and thrombosis risk requires ongoing investigation.
- Understanding these effects is crucial for patient safety and treatment decisions.
Purpose of the Study:
- To assess the procoagulant effects of conjugated estrogens in postmenopausal women.
- To compare the impact of conjugated estrogens on coagulation parameters with oral contraceptives.
- To evaluate changes in thrombin generation, fibrinolysis, and thrombelastograms.
Main Methods:
- 11 menopausal women received 1.25 mg daily of conjugated estrogens (Premarin).
- Coagulation tests, including thrombelastograms and euglobin lysis time, were performed after 5 and 21 days.
- Antithrombin III activity and fibrin monomers were also measured.
Main Results:
- A shift toward hypercoagulability was observed in thrombelastogram parameters.
- No significant changes in thrombin generation or euglobin lysis time were detected.
- Antithrombin III activity showed a less pronounced decrease compared to oral contraceptives.
- Fibrin monomers were detected in some participants during the first week.
Conclusions:
- Conjugated estrogen therapy may induce a mild hypercoagulable state in some menopausal women.
- The procoagulant effect appears less potent than that of oral contraceptives.
- Further research is needed to fully elucidate the long-term thrombotic risk associated with conjugated estrogens.